FDA Ephedrine Rule Cost-Benefit Analysis Needs Further Explanation - GAO
This article was originally published in The Tan Sheet
Executive Summary
FDA should be required to better explain the factors used in its cost-benefit analysis of the expected effects of the ephedrine proposed rule, the General Accounting Office states in a report on the rule released Aug. 4.
You may also be interested in...
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA's scientific justification for its proposed rule restricting the use of ephedrine alkaloids in dietary supplements is "open to question," GAO says in a report on the ephedrine proposed rule issued Aug. 4.
Ephedrine 8 mg dose limit, warnings against long-term intake proposed by agency.
EPHEDRINE ALKALOID PER-SERVING LIMIT OF 8 MG SUGGESTED BY FDA in a proposed rule published in the June 4 Federal Register. The rule is directed at dietary supplement products containing ephedrine alkaloids derived from raw botanicals -- products usually labeled as containing "ephedra," "Chinese ephedra" or "ma huang" that are sold for weight loss, increased energy and body building. The proposal does not apply to OTC drugs.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC